NASDAQ:TPST Tempest Therapeutics (TPST) Stock Forecast, Price & News $1.45 +0.01 (+0.69%) (As of 06/2/2023 ET) Add Compare Share Share Today's Range$1.42▼$1.5150-Day Range$1.37▼$3.7652-Week Range$1.06▼$4.21Volume82,278 shsAverage Volume69,563 shsMarket Capitalization$16.81 millionP/E RatioN/ADividend YieldN/APrice Target$10.00 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Tempest Therapeutics MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside1,164.4% Upside$18.33 Price TargetShort InterestHealthy1.52% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.36Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($2.19) to ($2.20) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.71 out of 5 starsMedical Sector798th out of 983 stocksPharmaceutical Preparations Industry400th out of 486 stocks 3.5 Analyst's Opinion Consensus RatingTempest Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $18.33, Tempest Therapeutics has a forecasted upside of 1,164.4% from its current price of $1.45.Amount of Analyst CoverageTempest Therapeutics has only been the subject of 2 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted1.52% of the float of Tempest Therapeutics has been sold short.Short Interest Ratio / Days to CoverTempest Therapeutics has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Tempest Therapeutics has recently increased by 144.20%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldTempest Therapeutics does not currently pay a dividend.Dividend GrowthTempest Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for TPST. Previous Next 1.9 News and Social Media Coverage News SentimentTempest Therapeutics has a news sentiment score of 0.36. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Tempest Therapeutics this week, compared to 1 article on an average week.Search InterestOnly 1 people have searched for TPST on MarketBeat in the last 30 days. This is a decrease of -83% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Tempest Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.14% of the stock of Tempest Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 29.32% of the stock of Tempest Therapeutics is held by institutions. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Tempest Therapeutics are expected to decrease in the coming year, from ($2.19) to ($2.20) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Tempest Therapeutics is -0.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Tempest Therapeutics is -0.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioTempest Therapeutics has a P/B Ratio of 1.53. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Tempest Therapeutics (NASDAQ:TPST) StockTempest Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development and discovery of small molecule drugs for the treatment of cancer. The company was founded in 2011 and is headquartered in Brisbane, CA.Read More Receive TPST Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Tempest Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address TPST Stock News HeadlinesMay 31, 2023 | finance.yahoo.comTempest to Present at the Jefferies Global Healthcare ConferenceMay 30, 2023 | markets.businessinsider.comAnalyst Ratings for Tempest TherapeuticsJune 4, 2023 | Behind the Markets (Ad)66,000% upside on tiny biotech?The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.May 25, 2023 | finance.yahoo.comTempest to Present Phase 1 Monotherapy and Combination Data at ASCO for TPST-1495 in Patients with Advanced CancersMay 25, 2023 | finance.yahoo.comTempest to Present Phase 1 Monotherapy and Combination Data at ASCO for TPST-1495 in Patients with Advanced CancersMay 19, 2023 | finance.yahoo.comTempest Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 17, 2023 | americanbankingnews.comTempest Therapeutics, Inc. Forecasted to Earn Q2 2023 Earnings of ($0.64) Per Share (NASDAQ:TPST)May 16, 2023 | americanbankingnews.comTempest Therapeutics, Inc. to Post Q2 2023 Earnings of ($0.52) Per Share, William Blair Forecasts (NASDAQ:TPST)June 4, 2023 | Behind the Markets (Ad)⚡ 2,467% Return on Israeli Laser Company?This advanced laser system is active in 80 countries around the world. And at the center of this massive market is a small firm in Israel. Our research shows that anyone who gets in today could see a return of 2,467%. But that's only if the company doesn't get taken over for a fast 300% gain first.May 12, 2023 | msn.comHC Wainwright & Co. Reiterates Tempest Therapeutics (TPST) Buy RecommendationMay 11, 2023 | finanznachrichten.deTempest Therapeutics: Tempest Reports First Quarter 2023 Financial Results and Provides Business UpdateMay 11, 2023 | markets.businessinsider.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Tempest Therapeutics (TPST), MannKind (MNKD) and Alkermes (ALKS)May 10, 2023 | finance.yahoo.comTempest Reports First Quarter 2023 Financial Results and Provides Business UpdateMay 10, 2023 | finance.yahoo.comTempest Reports First Quarter 2023 Financial Results and Provides Business UpdateMay 1, 2023 | msn.comTempest Therapeutics, Inc. (TPST) Upgraded to Buy: What Does It Mean for the Stock?May 1, 2023 | americanbankingnews.comTempest Therapeutics (NASDAQ:TPST) Price Target Raised to $14.00April 29, 2023 | marketwatch.com8-K: Tempest Therapeutics, Inc.April 29, 2023 | msn.comLadenburg Thalmann Maintains Tempest Therapeutics (TPST) Buy RecommendationApril 29, 2023 | americanbankingnews.comShort Interest in Tempest Therapeutics, Inc. (NASDAQ:TPST) Declines By 29.9%April 28, 2023 | markets.businessinsider.comTempest Announces Positive Results From Phase 1b/2 Trial Of TPST-1120 In Hepatocellular CancerApril 28, 2023 | msn.comTempest Soars after Positive Clinical Data for TPST-1120April 28, 2023 | msn.comTempest surges ~40% as TPST-1120 shows promise in liver cancer trialApril 28, 2023 | finance.yahoo.comTempest Announces Positive Early Results from Global Randomized Phase 1b/2 Combination Study of TPST-1120 in First-Line Hepatocellular CarcinomaApril 27, 2023 | finance.yahoo.comTempest to Report Early Results from Global Randomized Phase 1b/2 Combination Study of TPST-1120 in First-Line Hepatocellular CarcinomaApril 26, 2023 | benzinga.comTempest Announces TPST-1495 Poster Presentation at the 2023 ASCO Annual MeetingApril 26, 2023 | finance.yahoo.comTempest Announces TPST-1495 Poster Presentation at the 2023 ASCO Annual MeetingApril 17, 2023 | finance.yahoo.comTempest Announces New Translational and Preclinical Data Presented at the 2023 AACR Annual MeetingSee More Headlines TPST Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart TPST Company Calendar Last Earnings3/22/2023Today6/04/2023Next Earnings (Estimated)8/21/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:TPST CUSIPN/A CIK1544227 Webwww.millendo.com Phone415-798-8589FaxN/AEmployees14Year Founded2012Price Target and Rating Average Stock Price Forecast$18.33 High Stock Price Forecast$35.00 Low Stock Price Forecast$6.00 Forecasted Upside/Downside+589.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($2.63) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-35,710,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-153.57% Return on Assets-63.97% Debt Debt-to-Equity Ratio0.81 Current Ratio3.28 Quick Ratio3.28 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.95 per share Price / Book1.53Miscellaneous Outstanding Shares11,586,000Free Float10,990,000Market Cap$16.80 million OptionableNot Optionable Beta0.91 Social Links Key ExecutivesStephen R. BradyChief Executive Officer & DirectorThomas W. DubenskyPresident & DirectorNicholas MaestasSecretary, Vice President-Finance & StrategySam WhitingChief Medical Officer & Executive Vice PresidentDarrin BombaVice President-Clinical OperationsKey CompetitorsRenovoRxNASDAQ:RNXTPaxMedicaNASDAQ:PXMDAgeX TherapeuticsNYSE:AGEEdesa BiotechNASDAQ:EDSAMoleculin BiotechNASDAQ:MBRXView All CompetitorsInstitutional OwnershipSusquehanna International Group LLPBought 11,087 shares on 5/16/2023Ownership: 0.096%View All Institutional Transactions TPST Stock - Frequently Asked Questions Should I buy or sell Tempest Therapeutics stock right now? 4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Tempest Therapeutics in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" TPST shares. View TPST analyst ratings or view top-rated stocks. What is Tempest Therapeutics' stock price forecast for 2023? 4 analysts have issued 1-year target prices for Tempest Therapeutics' stock. Their TPST share price forecasts range from $6.00 to $35.00. On average, they anticipate the company's share price to reach $18.33 in the next twelve months. This suggests a possible upside of 1,164.4% from the stock's current price. View analysts price targets for TPST or view top-rated stocks among Wall Street analysts. How have TPST shares performed in 2023? Tempest Therapeutics' stock was trading at $1.15 on January 1st, 2023. Since then, TPST shares have increased by 26.1% and is now trading at $1.45. View the best growth stocks for 2023 here. Are investors shorting Tempest Therapeutics? Tempest Therapeutics saw a increase in short interest in the month of May. As of May 15th, there was short interest totaling 77,900 shares, an increase of 144.2% from the April 30th total of 31,900 shares. Based on an average daily trading volume, of 238,100 shares, the days-to-cover ratio is presently 0.3 days. Approximately 1.5% of the company's stock are short sold. View Tempest Therapeutics' Short Interest. When is Tempest Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, August 21st 2023. View our TPST earnings forecast. How were Tempest Therapeutics' earnings last quarter? Tempest Therapeutics, Inc. (NASDAQ:TPST) released its earnings results on Wednesday, March, 22nd. The company reported ($0.63) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.72) by $0.09. When did Tempest Therapeutics' stock split? Tempest Therapeutics shares reverse split before market open on Friday, June 25th 2021. The 1-15 reverse split was announced on Friday, June 25th 2021. The number of shares owned by shareholders was adjusted after the closing bell on Monday, June 28th 2021. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. What is Tempest Therapeutics' stock symbol? Tempest Therapeutics trades on the NASDAQ under the ticker symbol "TPST." Who are Tempest Therapeutics' major shareholders? Tempest Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional investors include Susquehanna International Group LLP (0.10%). Insiders that own company stock include Thomas W Dubensky and Thomas Woiwode. View institutional ownership trends. How do I buy shares of Tempest Therapeutics? Shares of TPST stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Tempest Therapeutics' stock price today? One share of TPST stock can currently be purchased for approximately $1.45. How much money does Tempest Therapeutics make? Tempest Therapeutics (NASDAQ:TPST) has a market capitalization of $16.80 million. The company earns $-35,710,000.00 in net income (profit) each year or ($2.63) on an earnings per share basis. How can I contact Tempest Therapeutics? Tempest Therapeutics' mailing address is 110 MILLER AVENUE SUITE 100, ANN ARBOR MI, 48104. The official website for the company is www.millendo.com. The company can be reached via phone at 415-798-8589 or via email at stephanie@sternir.com. This page (NASDAQ:TPST) was last updated on 6/4/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tempest Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.